3487911 Canada Inc, a 10% Holder, acquired 18,200 Common Shares on a direct ownership basis at prices ranging from $7.330 to $7.340 between March 25th, 2019 and March 26th, 2019. This represents a $133,538 investment into the company's shares and an account share holdings change of 0.1%.
Jonathan Goodman, CEO, Director and 10% Holder, acquired 5,200 Common Shares on a direct ownership basis at a price of $7.350 on March 25th, 2019. This represents a $38,220 investment into the company's shares and an account share holdings change of 1.2%.
Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.
No Comments